ES2111769T3 - Nuevos usos de il-10. - Google Patents

Nuevos usos de il-10.

Info

Publication number
ES2111769T3
ES2111769T3 ES93920050T ES93920050T ES2111769T3 ES 2111769 T3 ES2111769 T3 ES 2111769T3 ES 93920050 T ES93920050 T ES 93920050T ES 93920050 T ES93920050 T ES 93920050T ES 2111769 T3 ES2111769 T3 ES 2111769T3
Authority
ES
Spain
Prior art keywords
new uses
alone
optionally
manufacture
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93920050T
Other languages
English (en)
Inventor
Robert Coffman
Vries Jan E De
Waal Malefyt Rene De
Fiona Powrie
Donna Rennick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/932,900 external-priority patent/US5368854A/en
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2111769T3 publication Critical patent/ES2111769T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

SE PROPORCIONAN COMPOSICIONES Y METODOS PARA EL USO DE IL-4 Y/O IL-10, O ANTICUERPOS CONTRA IL-4 Y IL-10, PARA EL TRATAMIENTO DE UN NUMERO DE ENFERMEDADES. EN UNA REALIZACION, IL-10 SE UTILIZA PARA INHIBIR LA PRODUCCION DE IL-2 MEDIANTE LINFOCITOS NEOPLASTICOS, O PROLIFERACION DE CELULAS NEOPLASTICAS DEPENDIENTES DE IL-2. EN OTRA REALIZACION, IL-10 SE UTILIZA PARA TRATAR ENFERMEDADES INTESTINALES INFLAMATORIAS. EN OTRA REALIZACION, LOS ANTICUERPOS CONTRA IL-4 Y IL-10 SE UTILIZAN PARA AUMENTAR LOS NIVELES DE IFN-(TAU). EN OTRA REALIZACION, SE UTILIZA UNA COMBINACION DE IL-4 Y IL-10 PARA POTENCIAR LA INHIBICION DE IL-10 INTERMEDIO DE PRODUCCION DE CITOQUINA MEDIANTE CELULAS T. EN OTRA REALIZACION, IL-10, SOLO O EN COMBINACION CON IL-4, SE UTILIZA PARA INHIBIR REACCIONES DE HIPERSENSIBILIDAD DE TIPO RETARDADO. ESTA INVENCION PROPORCIONA ADEMAS COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UN CATALIZADOR FISIOLOGICAMENTE ACEPTABLE Y UNA COMBINACION DE IL-4 Y IL-10, O UNA COMBINACION DE ANTICUERPOSCONTRA IL-4 Y IL-10.
ES93920050T 1992-08-20 1993-08-18 Nuevos usos de il-10. Expired - Lifetime ES2111769T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/932,900 US5368854A (en) 1992-08-20 1992-08-20 Use of IL-10 to treat inflammatory bowel disease
US93395092A 1992-08-21 1992-08-21
US93341992A 1992-08-21 1992-08-21
US93346292A 1992-08-21 1992-08-21

Publications (1)

Publication Number Publication Date
ES2111769T3 true ES2111769T3 (es) 1998-03-16

Family

ID=27506019

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93920050T Expired - Lifetime ES2111769T3 (es) 1992-08-20 1993-08-18 Nuevos usos de il-10.

Country Status (23)

Country Link
EP (2) EP0671933B1 (es)
JP (1) JP3494647B2 (es)
KR (1) KR0170037B1 (es)
CN (1) CN1090204A (es)
AT (1) ATE162947T1 (es)
AU (1) AU680628B2 (es)
CA (1) CA2142861C (es)
CZ (1) CZ283488B6 (es)
DE (1) DE69316921T2 (es)
DK (1) DK0671933T3 (es)
ES (1) ES2111769T3 (es)
FI (1) FI950697A (es)
GR (1) GR3026635T3 (es)
HK (1) HK1004326A1 (es)
HU (1) HU220103B (es)
IL (1) IL106725A (es)
MX (1) MX9305054A (es)
MY (1) MY111402A (es)
PL (1) PL307566A1 (es)
RU (1) RU2120802C1 (es)
SK (1) SK21195A3 (es)
TW (1) TW243415B (es)
WO (1) WO1994004180A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155109A1 (en) * 1993-02-01 1994-08-18 Daniel Abramowicz Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
EE03451B1 (et) * 1994-07-05 2001-06-15 Steeno Research Group A/S Immunomodulaatorid
EP0793504B1 (en) * 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
EP0756871A1 (en) * 1995-08-01 1997-02-05 Institut Pasteur Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
KR20000005539A (ko) * 1996-04-17 2000-01-25 패트릭 티. 프렌더가스트 Dhea복합요법
WO1998027997A1 (en) * 1996-12-20 1998-07-02 Magainin Pharmaceuticals Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
AU770726B2 (en) * 1998-10-20 2004-02-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
DE60017115T2 (de) 1999-02-10 2005-12-08 Mitsubishi Pharma Corp. Amid-derivate und deren medizinische verwendung
JP2003518627A (ja) * 1999-12-03 2003-06-10 バクスター・インターナショナル・インコーポレイテッド 自動イムノアッセイシステムを用いる使用のための発熱性試験
AU8729101A (en) 2000-03-31 2001-10-15 Idec Pharma Corp Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
PE20060560A1 (es) 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
EP1880001B1 (en) 2005-05-31 2011-06-08 The Iams Company Feline probiotic lactobacilli
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
EP1931762B1 (en) * 2005-10-03 2012-12-05 Actogenix N.V. Use of recombinant yeast strain producing an anti -inflammatory compound in the manufacture of a medicament to treat colitis
BRPI0719446A2 (pt) * 2006-09-28 2013-12-10 Schering Corp Uso de il-10 peguilada para tratar câncer
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP2986306A4 (en) * 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
EP3369435B1 (en) 2013-07-18 2019-09-04 Xalud Therapeutics, Inc. Composition for the treatment of inflammatory joint disease
WO2015031316A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
CN114349858B (zh) * 2022-01-26 2022-07-01 优睿赛思(武汉)生物科技有限公司 抗人白介素-10高亲和力兔单克隆抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
DE69201128T2 (de) * 1991-01-16 1995-05-24 Schering Corp Behandlung von neoplastischen krankenheiten mit interleukin-10.
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair

Also Published As

Publication number Publication date
DE69316921D1 (de) 1998-03-12
CN1090204A (zh) 1994-08-03
RU2120802C1 (ru) 1998-10-27
MY111402A (en) 2000-04-29
KR950702841A (ko) 1995-08-23
IL106725A0 (en) 1993-12-08
IL106725A (en) 2000-12-06
PL307566A1 (en) 1995-05-29
FI950697A0 (fi) 1995-02-16
GR3026635T3 (en) 1998-07-31
EP0671933B1 (en) 1998-02-04
HUT70976A (en) 1995-11-28
TW243415B (es) 1995-03-21
CZ283488B6 (cs) 1998-04-15
HK1004326A1 (en) 1998-11-20
EP0801951A2 (en) 1997-10-22
CA2142861A1 (en) 1994-03-03
EP0801951A3 (en) 1998-05-20
EP0671933A1 (en) 1995-09-20
JP3494647B2 (ja) 2004-02-09
HU220103B (hu) 2001-10-28
MX9305054A (es) 1994-02-28
ATE162947T1 (de) 1998-02-15
AU5010893A (en) 1994-03-15
JPH08500362A (ja) 1996-01-16
FI950697A (fi) 1995-04-07
WO1994004180A3 (en) 1994-06-09
RU95108330A (ru) 1996-11-27
DK0671933T3 (da) 1998-09-23
KR0170037B1 (ko) 1999-02-01
SK21195A3 (en) 1996-10-02
CA2142861C (en) 2000-08-15
HU9500467D0 (en) 1995-04-28
CZ44195A3 (en) 1995-10-18
WO1994004180A2 (en) 1994-03-03
AU680628B2 (en) 1997-08-07
DE69316921T2 (de) 1998-06-04

Similar Documents

Publication Publication Date Title
ES2111769T3 (es) Nuevos usos de il-10.
IL128425A0 (en) Taxane derivatives their preparation and pharmaceutical compositions containing them
ATA188592A (de) Alkyl-bisacylphosphinoxide, diese enthaltende zusammensetzungen und ihre verwendung
DE3669315D1 (de) Phenoxyalkylaminopyrimidinderivate, deren herstellung und diese enthaltende insektizide und akarizide zusammensetzungen.
IL89921A (en) 1,3-dioxolane derivatives and pharmaceutical compositions containing the same
DE68912237T2 (de) Dampfsensitive Zusammensetzung sowie diese enthaltende sterilisierungsanzeigende Zusammensetzung.
DE3889197D1 (de) Klebstoff-Zusammensetzungen und diese Zusammensetzungen enthaltende Laminate.
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
DE69017969T2 (de) 2-Cyclohexylpropionsäure oder Derivate davon enthaltende Riechstoffzusammensetzung.
DE69327693D1 (de) Interferon-Alpha/Beta bindendes Protein, seine Herstellung und seine enthaltende pharmazeutische Zusammensetzungen
FI923751A (fi) Hexahydrobenso/f/kinolinoner
DE3863687D1 (de) Tinten-zusammensetzungen und deren zubereitung.
FR2661809B3 (fr) Diffuseur personnel de parfum ou de desodorisant.
DE3684756D1 (de) Durch (omega-amino)-alkanolgruppen substituierte aromatische derivate mit antimikrobenwirkung und diese enthaltende zusammensetzungen.
DE69012630D1 (de) Mittel gegen Ratten.
FR2676773B1 (fr) Rambarde de securite amovible.
MX9203784A (es) Composiciones para el tratamiento de osteoporosis en seres humanos.
FI921343A0 (fi) Kombinerat steriliserat varmvatten- och braennsystem.
ES549968A0 (es) Mejoras en el objeto de la patente de invencion n.548103 por: procedimiento para la conservacion de vegetales.
IT8919204A0 (it) Composizione per la prevenzione e la cura di parodontopatte.
BR1101031A (pt) Derivado de monobiguanida, e desinfetantes contendo o derivado
ITRM920930A0 (it) Impiego del glutatione per la preparazione di composizioni farmaceutiche ad attivita' antivirale.
ES555466A0 (es) Mejoras introducidas en el objeto de la patente de invencion 516.212 por perfeccionamientos introducidos en atomizadores agricolas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 671933

Country of ref document: ES